NASDAQ: BRKR · Medical Devices
Bruker (BRKR) fair value: undervalued or overvalued?
As of 31 Oct 2026, Faircurve's model values Bruker (BRKR) at $63.61 a share. The stock last closed at $58.06, which puts the model's fair value 9.6% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 5 Nov 2026. Bruker Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 31 Oct 2026 held the fair value at $63.61, within 1% of the run of 24 Oct 2026.
What the model makes of itThe price of $58.06 is 9.6% below it: Fairly valued, on a high evidence grade.
What's nextNext report on 11 Feb 2027. Options prices imply a move of about 17% either way over the next month. The next weekly run is on Saturday 7 Nov 2026.
What price range does the model give BRKR?
The calibrated range for BRKR over 63 trading days is $48.69 to $72.07. It sits around the last close, and its width comes from the volatility that BRKR's own options imply (59% a year), calibrated weekly against realised prices (n = 6,661 past valuations, refreshed 31 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $48.41 to $82.10. In 62% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 31 Oct 2026
Bruker Corporation is a prominent global developer, manufacturer and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions.
Faircurve's model put the fair value of Bruker Corporation at $63.61 a share on 31 Oct 2026, the midpoint of 2,000 simulations. The previous run, on 24 Oct 2026, gave $63.69, so the fair value moved -0.1%. The calibrated range over 63 trading days runs from $53.52 to $79.14. It is built from the volatility the stock's own options imply and calibrated weekly against realised prices, using 6,661 past valuations. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High. The grade weighs input completeness, comparable companies and how closely they agree, and the width of outcomes. It does not say whether the fair value is right.
Bruker scores 46 out of 100 on the model's overall quality measure, against comparable companies. Three factors stand out most. Balance sheet scores 21, with net debt to EBITDA at 6.99x against a peer median of 1.01x. Growth quality scores 36, with trailing revenue growth at 2.1% against a peer median of 3.8%. Profitability scores 42, with ROIC at 3.0% against a peer median of 6.1%. The model compares Bruker with Bio-Rad Laboratories, Globus Medical, Align Technology, Penumbra, Haemonetics and LivaNova.
Written from the figures on this page for the 31 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does BRKR report earnings, and how has the stock reacted?
Bruker's next earnings report is scheduled for 11 Feb 2027. Companies can move their dates.
Options prices on 5 Nov 2026 imply a move of about 11.7% in either direction through the nearest expiry, about 14 days out. That is the size the market is pricing, not a direction. BRKR's 30 day implied volatility works out to about 17.1% over one month.
On 5 Nov 2026 BRKR moved 9.0% in one session, against the 3.7% a day that options had priced: 2.4 times the implied size, around an earnings report.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across BRKR's last 8 reports, ignoring direction, was 8.8%.
What the options market has priced for a month's move in BRKR
How does BRKR score on business quality?
Bruker's overall quality score is 46 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 42 | 3.0%ROIC | 6.1% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 67 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 36 | 2.1%Revenue growth, trailing | 3.8% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 37 | 0.0%Net buybacks / market value | 0.6% |
| Balance sheetNet debt to EBITDA and interest coverage. | 21 | 6.99xNet debt / EBITDA | 1.01x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 67 | 4.2 ptsEBITDA margin downside volatility, 5y | 5.9 pts |
How does BRKR compare with similar companies?
The companies in medical devices closest to Bruker in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| BIO Bio-Rad Laboratories, Inc. | $369.00 | $350.46 | -5.0% | Fairly valued |
| PODD Insulet Corp. | $156.12 | $193.15 | +23.7% | Low evidence grade |
| GMED Globus Medical, Inc. | $81.44 | $91.57 | +12.4% | Fairly valued |
| ALGN Align Technology, Inc. | $159.37 | $188.05 | +18.0% | Undervalued |
| PEN Penumbra, Inc. | $321.11 | $291.62 | -9.2% | Fairly valued |
| HAE Haemonetics Corporation | $124.11 | $117.17 | -5.6% | Fairly valued |
| GKOS Glaukos Corporation | $219.98 | $220.17 | +0.1% | Data under review |
| LIVN LivaNova PLC | $91.14 | $88.46 | -2.9% | Fairly valued |
What the comparable companies' multiples alone would give for BRKR, the peer-implied price, is $72.55 a share on this run. The fair value weighs that against the company's own multiple.
Bruker at a glance
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions.
- Market value
- $8.7B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $3.7B
- Consensus revenue growth, next fiscal year
- +3.5%
- Analysts with estimates
- 6
- Beta to the US market
- 1.41
- First valued by Faircurve
- 11 Jul 2026
At the close of 5 Nov 2026, 56.0% of the 1,065 graded US stocks the model covers traded below the model's fair value. BRKR was among them.
How the fair value is worked out: the model prices Bruker on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 24 Oct 2026 the model's fair value for BRKR was $63.69. As of 31 Oct 2026 it is $63.61, a change of -0.1%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Bruker's valuation
Is Bruker stock undervalued or overvalued?
On Faircurve's model, BRKR reads as Fairly valued as of 31 Oct 2026. The model's fair value is $63.61 a share against a last close of $58.06, a gap of +9.6%.
What is BRKR's fair value?
$63.61 a share as of 31 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $48.41 to $82.10.
What price range does the model give BRKR?
$48.69 to $72.07 over 63 trading days. Ranges built this way held the price 60% of the time across 6,661 past valuations, refreshed 31 Oct 2026.
When does Bruker report earnings next?
The next report is scheduled for 11 Feb 2027. Companies can move their dates.
How much has BRKR moved on past earnings reports?
Across its last 8 reports the median two session move was 8.8%, ignoring direction. The largest was -18.4% around the report of 4 Aug 2026.
How confident is the model in this valuation?
The model's evidence grade for BRKR is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on BRKR
The model holds no idea open on BRKR today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on BRKR with their outcomes. A free account is enough.